Inovio Pharmaceuticals Inc (NASDAQ:INO)

7.08
Delayed Data
As of Feb 27
 +0.045 / +0.64%
Today’s Change
6.33
Today|||52-Week Range
15.56
-22.93%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$426.0M

Company Description

Inovio Pharmaceuticals, Inc. develops synthetic vaccines and immune therapies for cancers and infectious diseases. Its SynCon vaccines are generating immune responses with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth and response rate. The company develops DNA vaccines, such as immune therapies to prevent or treat cancers, HIV, hepatitis C virus and other chronic infectious diseases. Inovio Pharmaceuticals was founded on June 29, 1983 and is headquartered in Blue Bell, PA.

Contact Information

Inovio Pharmaceuticals, Inc.
1787 Sentry Parkway West
Blue Bell Pennsylvania 19422-2200
P:(267) 440-4200
Investor Relations:
(858) 410-3101

Employees

Shareholders

Individual stakeholders6.03%
Mutual fund holders16.28%
Other institutional12.92%

Top Executives

J. Joseph KimPresident, Chief Executive Officer & Director
Niranjan Y. SardesaiChief Operating Officer
Peter D. KiesChief Financial Officer
Jessica LeeVice President-Clinical Operations
Mark L. BagarazziChief Medical Officer

To view my watchlist

Not a member yet?

Sign up now for a free account